Reversing immune resistance in HER2-negative breast cancer
Part of Cancer clinical trials.
This trial tests a new treatment to see if it can reverse resistance to immunotherapy in people with HER2-negative breast cancer. It's for patients whose cancer has gotten worse after immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can perform daily activities with little or no help (ECOG 0-2).
- You have metastatic or advanced breast cancer that is either luminal (hormone receptor positive, HER2-negative) or triple negative (no receptors).
- Your cancer has worsened after immunotherapy (combined with other treatments) for metastatic disease.
- You have measurable tumors that can be tracked by scans (RECIST 1.1).
- You have adequate organ function and blood test results within normal limits in the last 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial compares two different chemotherapy combinations (one with a newer type of paclitaxel called polymeric micelles, plus an immunotherapy drug called adebelimab) against a standard taxane plus HP regimen, as first-line treatment for advanced HER2-positive breast cancer. The goal is to see if the new combination works better at controlling the cancer.
This study tests a new combination of drugs—cromolyn, TQB2102, and panpulimab—for women with triple negative breast cancer that has not responded to previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer and give you another treatment option.
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.